Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
9/8/26 Bristol Myers Squibb (BMY) Arlo-cel for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
9/2/26 Jiangsu Hengrui Pharmaceuticals (600276:SS) SHR-1918 for Dyslipidemia / Hypercholesterolemia Subscribers Only Subscribers Only Subscribers Only
9/2/26 Jiangsu Hengrui Pharmaceuticals (600276:SS) SHR-1918 for Homozygous Familial Hypercholesterolemia (HoFH) Subscribers Only Subscribers Only Subscribers Only
9/1/26 Alumis (ALMS) envudeucitinib for Systemic Lupus Erythematosus (SLE) Subscribers Only Subscribers Only Subscribers Only
8/29/26 Tenax Therapeutics (TENX) Simdax for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
07/31/2025 Subscribers Only Subscribers Only Regulatory - sNDA/sBLA Filing
09/30/2025 Subscribers Only Subscribers Only Trial Announcement - Trial Completion
10/28/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/31/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/11/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update